Biopsy Breast (Modified Radical Mastectomy +ER+PR+HER2NEU) Test
Short Name: Breast Biopsy MRM + IHC
Also known as: Modified Radical Mastectomy Biopsy, Breast Cancer Receptor Status Test, ER/PR/HER2 IHC Panel
Biopsy Breast (Modified Radical Mastectomy +ER+PR+HER2NEU) Test test available at DNA Labs India for ₹8,250. Uses Histopathology, Immunohistochemistry (IHC) on Tissue (Breast tumor specimen in 10% Neutral Buffered Formalin) samples. Results in Results are typically available within 6 days after the laboratory receives the specimen. The report will be sent to your doctor, who will discuss the findings and treatment options with you.. Free home collection in 300+ cities across India.
🩺 Medically Reviewed By
Dr Pasupathy Arumugam
Consultant Pathologist · Reg: 21521
Last reviewed: September 7, 2026
Overview
The purpose of this test is to confirm the presence of breast cancer, determine the histological type and grade, and assess the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2/neu). These biomarkers are essential for classifying the tumor into molecular subtypes (Luminal A, Luminal B, HER2-enriched, or Triple-negative), which directly influences treatment strategy and prognosis. The results help oncologists decide on the most effective therapeutic approach, including endocrine therapy, chemotherapy, or targeted therapy, thereby improving patient outcomes.
- Test Code
- 6063
- CPT Code
- 88307, 88360, 88361
- ICD Code
- C50.9
- Price
- ₹8,250
- Sample Type
- Tissue (Breast tumor specimen in 10% Neutral Buffered Formalin)
- Result Time
- Results are typically available within 6 days after the laboratory receives the specimen. The report will be sent to your doctor, who will discuss the findings and treatment options with you.
- Fasting Required
- No
- Method
- Histopathology, Immunohistochemistry (IHC)
Sample Collection
No special preparation is required. The test is performed on a surgical specimen obtained during mastectomy. Ensure the specimen is placed in 10% Neutral Buffered Formalin immediately after removal and sent to the laboratory with a doctor's prescription.
Method: Surgical biopsy / Modified Radical Mastectomy specimen
Laboratory Analysis
The surgical specimen is collected by the surgeon in the operating room. It is then transferred to a formalin container and transported to the laboratory at ambient temperature.
Report Delivery
The specimen is processed in the laboratory, embedded in paraffin, sectioned, and stained. IHC is performed for ER, PR, and HER2. The report is generated within 6 days.
Timeline: Results are typically available within 6 days after the laboratory receives the specimen. The report will be sent to your doctor, who will discuss the findings and treatment options with you.
Patient Instructions
About This Test
Who Should Get This Test
The purpose of this test is to confirm the presence of breast cancer, determine the histological type and grade, and assess the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2/neu). These biomarkers are essential for classifying the tumor into molecular subtypes (Luminal A, Luminal B, HER2-enriched, or Triple-negative), which directly influences treatment strategy and prognosis. The results help oncologists decide on the most effective therapeutic approach, including endocrine therapy, chemotherapy, or targeted therapy, thereby improving patient outcomes.
How to Prepare
- Specimen must be placed in 10% Neutral Buffered Formalin (volume at least 10 times the tissue volume)
- Label the container with patient name, ID, and date of collection
- Transport at room temperature to the laboratory as soon as possible
- Do not freeze the specimen
- Include clinical history and relevant imaging findings
Doctor's Notes
Reviewed by Dr Pasupathy Arumugam — MBBS, MD (Pathology) · Reg. No. 21521
"This comprehensive histopathological evaluation is essential for determining the molecular subtype of breast cancer, guiding targeted therapy decisions, and predicting prognosis. Accurate ER, PR, and HER2 status is critical for personalized treatment planning."
Last medically reviewed: September 7, 2026
Test Parameters & Specifications
Sample Stability
- Unlabeled or mislabeled specimen
- Specimen not in formalin or dried out
- Inadequate tissue sample (e.g., only necrotic tissue)
- Specimen received after prolonged delay (>72 hours) without proper fixation
Understanding Your Results
Luminal A-like subtype; likely to benefit from endocrine therapy; chemotherapy may be added based on risk
Recommendation: Endocrine therapy (e.g., tamoxifen, aromatase inhibitor) with or without chemotherapy
Luminal B-like subtype; aggressive; benefits from endocrine therapy plus anti-HER2 therapy
Recommendation: Endocrine therapy + trastuzumab (Herceptin) + chemotherapy
HER2-enriched subtype; aggressive; responds to anti-HER2 therapy
Recommendation: Anti-HER2 therapy (trastuzumab, pertuzumab) + chemotherapy
Triple-negative breast cancer; high-grade; limited targeted options; chemotherapy is mainstay
Recommendation: Chemotherapy (e.g., anthracycline, taxane); consider PARP inhibitors if BRCA mutation
Inconclusive; requires further testing by FISH or CISH to determine gene amplification
Recommendation: Perform HER2 FISH/CISH test
Consult your oncologist immediately if you have been diagnosed with breast cancer or if you experience any symptoms such as a new breast lump, persistent pain, nipple discharge, or skin changes. Early consultation and testing can significantly improve treatment outcomes.
Limitations
- ⚠IHC results are semi-quantitative and may require confirmatory FISH/CISH for equivocal HER2 (2+) cases
- ⚠Tissue sampling may not represent the entire tumor heterogeneity
- ⚠Results are dependent on tissue processing and fixation quality
- ⚠Not a substitute for clinical staging or imaging
Risks & Considerations
- ●Surgical risks (bleeding, infection, anesthesia complications) associated with mastectomy
- ●Lymphedema (arm swelling) due to lymph node removal
- ●Pain and scarring at the surgical site
- ●Psychological impact of breast removal
Interfering Factors
- ●Improper fixation of tissue (delay in formalin fixation)
- ●Inadequate tissue sample or necrosis
- ●Decalcification of bone-containing tissue
- ●Prior chemotherapy or radiation therapy may alter receptor expression
- ●Technical issues in IHC staining (e.g., antigen retrieval, antibody quality)
Compare With Similar Tests
| Test | Biopsy Breast (Modified Radical Mastectomy +ER+PR+HER2NEU) | Core Needle Biopsy | Fine Needle Aspiration (FNA) | Excisional Biopsy |
|---|---|---|---|---|
| Comparison | Biopsy Breast (Modified Radical Mastectomy +ER+PR+HER2NEU) |
Frequently Asked Questions
What is the cost of Biopsy Breast (Modified Radical Mastectomy + ER + PR + HER2NEU) at DNA Labs India?
What is the sample type required for this test?
How long does it take to get the report?
Is fasting required before this test?
What is the purpose of ER, PR, and HER2 testing?
Can this test be done at home?
What does HER2 positive mean?
What is the difference between ER/PR and HER2?
Is a doctor's prescription required for this test?
What is the turnaround time for the report?
Are there any risks associated with the biopsy?
Can this test be performed on a core needle biopsy sample?
Related Tests
Reference Laboratory Services
We serve as a reference laboratory for hospitals and clinics across India. Send samples from your facility with same-day pickup, priority processing, and results delivered through our online portal. Competitive institutional pricing available.
Your Data Privacy
Your medical data is protected under Indian law.
✓ Stored in India: All patient records are stored on servers located in India. No data is transferred outside the country.
✓ DPDP Act Compliant: Under the Digital Personal Data Protection Act 2023, you can request deletion of your records at any time by contacting support.
Book Your Test
Enter your details and we'll connect you within 15 minutes.